US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

365.94

+0.67000.18%

Post-market: 365.940.00000.00%19:30 EDT

Volume:328.88K

Turnover:121.41M

Market Cap:41.72B

PE:65.47

High:376.50

Open:370.00

Low:365.79

Close:365.27

52wk High:385.22

52wk Low:253.95

Shares:114.00M

Float Shares:80.95M

Volume Ratio:0.75

T/O Rate:0.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):5.59

EPS(LYR):2.47

ROE:14.66%

ROA:7.46%

PB:8.06

PE(LYR):148.15

Loading ...

Overview Company News Filings

BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope

BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial

BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors

BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units

BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk

BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers

BeOne Medicines (ONC) Gets a Buy from Barclays

BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses

MT Newswires Live

BeOne Medicines announces presentation of Phase 3 data in CLL patients

BEIGENE Announces Grant of Restricted Share Units

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)

Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)

BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says

MT Newswires Live

Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)

TD Cowen Remains a Buy on BeOne Medicines (ONC)

Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)

RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)

Beone Medicines : RBC Raises Target Price to $436 From $425

THOMSON REUTERS

BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026

MT Newswires Live

New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/ONC/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":365.94,"timestamp":1790798400000,"preClose":365.27,"halted":0,"volume":328879,"hourTrading":{"tag":"盘后","latestPrice":365.94,"preClose":365.94,"latestTime":"19:30 EDT","volume":2211,"amount":809100.6246,"timestamp":1790811003642,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0018342595887973717,"floatShares":80952700,"shares":113999999,"eps":5.589356,"marketStatus":"Not Yet Opened","change":0.67,"latestTime":"09-30 16:00:00 EDT","open":370,"high":376.5,"low":365.79,"amount":121410990.95706,"amplitude":0.029321,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.589356,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":365.27,"preHourTrading":{"tag":"盘前","latestPrice":370.63,"preClose":365.27,"latestTime":"09:29 EDT","volume":25823,"amount":9437618.57528,"timestamp":1790774999999,"change":5.36,"changeRate":0.014674,"amplitude":0.010869},"postHourTrading":{"tag":"盘后","latestPrice":365.94,"preClose":365.94,"latestTime":"19:30 EDT","volume":2211,"amount":809100.6246,"timestamp":1790811003642,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.745695,"impliedVol":0.3618,"impliedVolPercentile":0.1833},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":80952700,"roa":"7.46%","roe":"14.66%","lyrEps":2.469999,"volumeRatio":0.745695,"shares":113999999,"dividePrice":0,"high":376.5,"amplitude":0.029321,"preClose":365.27,"low":365.79,"week52Low":253.9475,"pbRate":"8.06","psRate":"6.81","week52High":385.22,"institutionHeld":0,"latestPrice":365.94,"eps":5.589356,"divideRate":0,"volume":328879,"delay":0,"ttmEps":5.589356,"open":370,"prevYearClose":303.81,"prevWeekClose":360.85,"prevMonthClose":359.58,"prevQuarterClose":284.97,"fiveDayClose":365,"twentyDayClose":358.655,"sixtyDayClose":308.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2026-11-10","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1794301200000,"name":null,"time":"Pre-MKt","dateTimestamp":1794286800000,"actualEps":null},{"market":"US","date":"2026-08-05","symbol":"ONC","fiscalQuarterEnding":"2026/06","expectedEps":1.4,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":2.05},{"market":"US","date":"2026-05-06","symbol":"ONC","fiscalQuarterEnding":"2026/03","expectedEps":0.73,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778040000000,"reportTimeType":"post","actualEps":1.96},{"market":"US","date":"2026-02-26","symbol":"ONC","fiscalQuarterEnding":"2025/12","expectedEps":1.6,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"pre","actualEps":0.58},{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2963,"buy":0.7037,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7037,"analysts":27,"updateTime":1783915200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-09-29","current":65.47087,"percent":0.716239,"low":-217.585346,"twenty":-71.906091,"median":-24.111496,"eighty":109.091763,"high":609.337035,"avg":44.881671,"sd":207.175492,"marketCap":41728588859},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198},{"date":"2026-01-16","current":546.090088,"twenty":-85.828543,"median":-40.382553,"eighty":-21.503627,"marketCap":37434475537},{"date":"2026-01-23","current":546.929506,"twenty":-85.639801,"median":-40.307741,"eighty":-21.22036,"marketCap":37492017667},{"date":"2026-01-30","current":564.993144,"twenty":-85.550958,"median":-40.153659,"eighty":-20.966373,"marketCap":38730280050},{"date":"2026-02-06","current":560.150346,"twenty":-85.195011,"median":-40.102874,"eighty":-20.825389,"marketCap":38398306221},{"date":"2026-02-13","current":559.214072,"twenty":-84.275105,"median":-39.916618,"eighty":-20.627155,"marketCap":38334124614},{"date":"2026-02-20","current":572.225057,"twenty":-83.309792,"median":-39.846883,"eighty":-20.486836,"marketCap":39226027634},{"date":"2026-02-27","current":124.64483,"twenty":-82.630374,"median":-39.542215,"eighty":-20.122622,"marketCap":35764714896},{"date":"2026-03-06","current":113.265677,"twenty":-81.639564,"median":-39.274234,"eighty":-19.815709,"marketCap":32499660582},{"date":"2026-03-13","current":110.254986,"twenty":-80.905934,"median":-38.936161,"eighty":-19.52935,"marketCap":31635793773},{"date":"2026-03-20","current":109.257937,"twenty":-80.698984,"median":-38.812817,"eighty":-19.378455,"marketCap":31349707731},{"date":"2026-03-27","current":107.028105,"twenty":-78.593786,"median":-38.554628,"eighty":106.63856,"marketCap":30709895147},{"date":"2026-04-02","current":119.197503,"twenty":-77.951,"median":-38.396659,"eighty":109.305857,"marketCap":34201697271},{"date":"2026-04-10","current":121.122038,"twenty":-77.761122,"median":-38.192039,"eighty":109.972102,"marketCap":34753909865},{"date":"2026-04-17","current":123.949552,"twenty":-77.38927,"median":-37.882149,"eighty":113.865362,"marketCap":35565216938},{"date":"2026-04-24","current":115.875632,"twenty":-77.050014,"median":-37.033118,"eighty":115.720164,"marketCap":33248542844},{"date":"2026-05-01","current":114.357667,"twenty":-76.68,"median":-35.397875,"eighty":115.720164,"marketCap":32812988374},{"date":"2026-05-08","current":68.695502,"twenty":-76.462018,"median":-34.468285,"eighty":115.560959,"marketCap":35242166242},{"date":"2026-05-15","current":66.012693,"twenty":-76.246744,"median":-33.418249,"eighty":115.518333,"marketCap":33865831800},{"date":"2026-05-22","current":67.096218,"twenty":-76.102676,"median":-31.546239,"eighty":115.492019,"marketCap":34421701930},{"date":"2026-05-29","current":62.970154,"twenty":-75.880486,"median":-30.693232,"eighty":115.373164,"marketCap":32304948475},{"date":"2026-06-05","current":60.662245,"twenty":-75.223997,"median":-29.59006,"eighty":115.163248,"marketCap":31120945098},{"date":"2026-06-12","current":56.401824,"twenty":-74.640704,"median":-29.253094,"eighty":114.989528,"marketCap":28935263747},{"date":"2026-06-18","current":56.924083,"twenty":-74.490547,"median":-29.223519,"eighty":114.833736,"marketCap":29203193149},{"date":"2026-06-26","current":59.667569,"twenty":-74.312777,"median":-29.026044,"eighty":114.683445,"marketCap":30610656318},{"date":"2026-07-02","current":63.004827,"twenty":-74.195313,"median":-28.914242,"eighty":114.357667,"marketCap":32322736319},{"date":"2026-07-10","current":65.624791,"twenty":-74.135535,"median":-28.781271,"eighty":113.811576,"marketCap":33666830293},{"date":"2026-07-17","current":68.786518,"twenty":-74.11053,"median":-28.668245,"eighty":113.265677,"marketCap":35288859332},{"date":"2026-07-24","current":70.81271,"twenty":-74.11053,"median":-28.275697,"eighty":112.626442,"marketCap":36328336476},{"date":"2026-07-31","current":69.796363,"twenty":-73.864189,"median":-27.361812,"eighty":112.074132,"marketCap":35806930294},{"date":"2026-08-07","current":57.188468,"twenty":-73.321375,"median":-26.690447,"eighty":111.218799,"marketCap":37498879034},{"date":"2026-08-14","current":61.733374,"twenty":-72.9906,"median":-26.519964,"eighty":110.411886,"marketCap":40479005230},{"date":"2026-08-21","current":64.013629,"twenty":-72.865597,"median":-26.24637,"eighty":109.877808,"marketCap":41974184913},{"date":"2026-08-28","current":64.591063,"twenty":-72.771126,"median":-25.664335,"eighty":109.774239,"marketCap":42352812163},{"date":"2026-09-04","current":62.889975,"twenty":-72.657077,"median":-24.959227,"eighty":109.586422,"marketCap":41237396750},{"date":"2026-09-11","current":59.26931,"twenty":-72.278458,"median":-24.808073,"eighty":109.442662,"marketCap":38863301558},{"date":"2026-09-18","current":61.291195,"twenty":-72.041871,"median":-24.46985,"eighty":109.305857,"marketCap":40189065444},{"date":"2026-09-25","current":62.420051,"twenty":-71.960403,"median":-24.157208,"eighty":109.158233,"marketCap":40929264663},{"date":"2026-09-29","current":63.639078,"twenty":-71.906091,"median":-24.111496,"eighty":109.091763,"marketCap":41728588859}],"updateTime":1790816751844},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646802037","title":"BeOne Medicines’ Real‑World Lung Cancer Study Puts Tislelizumab Under the Market Microscope","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802037?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:31","pubTimestamp":1782405082,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running an observational study called “A Real-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-realworld-lung-cancer-study-puts-tislelizumab-under-the-market-microscope?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4585","BK4139","BK4588","ONC","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644808016","title":"BeOne Medicines (ONC) Investors Track New Data from BeiGene’s Chronic Urticaria Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644808016","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644808016?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800347,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) investors are watching a new update on a BeiGene ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-onc-investors-track-new-data-from-beigenes-chronic-urticaria-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","MDCO","BK4139","BK4588","BK4526","ONC","ISBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644809090","title":"BeOne Medicines’ BGB-45035 Trial Completion: What Early Skin Data Could Mean for ONC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644809090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644809090?lang=en_us&edition=fundamental","pubTime":"2026-06-19 00:32","pubTimestamp":1781800331,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The Phase 1a/1b study, officially titled “Phase 1a/1b Randomized Study ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-bgb-45035-trial-completion-what-early-skin-data-could-mean-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4588","BK4585","MDCO","BK4211","BK4139","BGB","BK4526","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162658338","title":"BEIGENE Announces Grant of Share Options, Restricted Share Units, and Performance Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162658338","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162658338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:21","pubTimestamp":1781788869,"startTime":"0","endTime":"0","summary":"The pharmaceutical company BEIGENE (06160) has disclosed the granting of share-based awards to certain recipients.On June 11, 2026, the board of directors, the compensation committee, and/or the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770034418.SGD","BK4585","LU2328871848.SGD","BK4139","LU1969619763.USD","LU1251922891.USD","BK1588","688235","LU1303224171.USD","BK1583","BK1500","LU0307460666.USD","06160","LU0588546209.SGD","BK4588","ONC","BK1161","BK0239","BK4526","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644370681","title":"BeOne Revenue Expected to Grow on Strong Brukinsa Sales -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2644370681","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644370681?lang=en_us&edition=fundamental","pubTime":"2026-06-18 16:39","pubTimestamp":1781771940,"startTime":"0","endTime":"0","summary":"0839 GMT - BeOne Medicine's revenue is forecast to reach $6.5 billion in 2026, driven by flagship cancer drug Brukinsa, which helped turn its operating margins positive last year, Morningstar analyst Kai Wang says. He sees the stock as undervalued, citing potential sales growth of its chronic lymphocytic leukemia treatment Brukinsa and its other core product Beqalzi, which is projected to generate $1 billion in sales by 2035. Wang estimates margin expansion of 400 basis points over the long term, as Brukinsa continues to scale out and capture more market share. Beyond 2026, Morningstar forecasts Brukinsa revenue growth in the high teens annually before slowing to 6% by 2032, when its patent expires. It initiates coverage of BeOne's H-shares with a fair value estimate of HK$214. The stock closed at HK$163.70. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4526","BK4585","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644728385","title":"BeOne Medicines Advances BGB-58067 With Key Drug-Interaction Study in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2644728385","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644728385?lang=en_us&edition=fundamental","pubTime":"2026-06-18 00:32","pubTimestamp":1781713967,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines (ONC) is running a Phase 1 study called “An Open-Label,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-bgb-58067-with-key-drug-interaction-study-in-healthy-volunteers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCO","BK4588","BK4585","BGB","ONC","BK4526","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643276720","title":"BeOne Medicines (ONC) Gets a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2643276720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643276720?lang=en_us&edition=fundamental","pubTime":"2026-06-15 16:37","pubTimestamp":1781512665,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beone-medicines-onc-gets-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139","BK4588","BK4526","MDCO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267757","title":"BeOne Says Updated Results for Cancer Drug Tacabrutideg Show 'Durable' Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267757?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:21","pubTimestamp":1781263301,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Friday that new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed \"durable responses\" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.Data from 67 patients with relapsed or refractory CLL/SLL treated with tacabrutideg across multiple dose levels showed an overall response rate of 85.1% and a 24-month progression-free survival rate of 53.8%. BeOne said tacabrutideg was generally well tolerated and no new toxicities were identified.In patients with relapsed or refractory Waldenstrom macroglobulinemia, tacabrutideg achieved a major response rate of 76.3%, a very good partial response rate of 30.2% and a 15-month progression-free survival rate of 70.4%.The data were announced at the European Hematology Association Congress in Stockholm.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","ONC","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281672","title":"BeOne Medicines announces presentation of Phase 3 data in CLL patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281672","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281672?lang=en_us&edition=fundamental","pubTime":"2026-06-11 19:40","pubTimestamp":1781178008,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-medicines-announces-presentation-of-phase-3-data-in-cll-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-medicines-announces-presentation-of-phase-3-data-in-cll-patients-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO","BK4588","BK4585","BK4526","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162679995","title":"BEIGENE Announces Grant of Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1162679995","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162679995?lang=en_us&edition=fundamental","pubTime":"2026-06-05 17:16","pubTimestamp":1780650982,"startTime":"0","endTime":"0","summary":"BEIGENE (HKEX: 06160) has issued an announcement regarding a grant of restricted share units.On June 1, 2026, the Board's Compensation Committee, in accordance with the terms of the 2016 Option and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK1500","ONC","BK1583","06160","LU1251922891.USD","LU1719994722.HKD","BK4585","BK1161","BK4139","LU1770034418.SGD","LU1969619763.USD","BK1588","688235","LU0588546209.SGD","LU1303224171.USD","BK4588","LU0307460666.USD","LU2328871848.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640186410","title":"Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640186410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640186410?lang=en_us&edition=fundamental","pubTime":"2026-06-04 02:00","pubTimestamp":1780509641,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-repligen-rgen-vaxcyte-pcvx-and-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0029874061.USD","BK4588","LU0757428866.USD","BK4581","ONC","LU0106261612.USD","BK4139","BK4526","LABU","LU1815336091.USD","LU0053671581.USD","BK4585","HCSG","RGEN","IE0009354923.USD","LU0128526141.USD","XLV","LU0012050646.USD","BK4121","XBI","MDCO","PCVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972140","title":"Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640972140?lang=en_us&edition=fundamental","pubTime":"2026-06-03 16:17","pubTimestamp":1780474659,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $409.00. Darout covers th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-beone-medicines-onc-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640463941","title":"BeOne Medicines Solid Tumor Data Boost Confidence in Long-term Growth, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2640463941","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640463941?lang=en_us&edition=fundamental","pubTime":"2026-06-02 23:04","pubTimestamp":1780412648,"startTime":"0","endTime":"0","summary":"BeOne Medicines  reported encouraging data from three solid tumor programs, strengthening confidence in its competitive potential and long-term growth, RBC Capital Markets said in a note Tuesday.The company on Monday presented \"promising\" data on a CDK4 inhibitor for breast cancer, a GPC3-4-1BB bispecific antibody for hepatocellular carcinoma, and a B7-H4 antibody-drug conjugate for ovarian cancer.Analyst Leonid Timashev said each therapy appears to be delivering on its promised profile, with potential safety or efficacy advantages that could support best-in-class positioning or at least strong competitiveness over the coming years.Although investors have generally been skeptical of BeOne Medicines' solid tumor portfolio, RBC believes the building blocks for success are becoming increasingly visible. As a result, the firm now estimates that the company could generate up to $4.8 billion in solid tumor sales by 2035.\"While more data, and in some cases, optimization is still needed, we th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","BK4526","ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943710","title":"Analysts Conflicted on These Healthcare Names: BeOne Medicines (ONC), Moderna (MRNA) and Danaher (DHR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943710?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:00","pubTimestamp":1780405239,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeOne Medicines (ONC), Moderna (MRNA) and Danaher ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-beone-medicines-onc-moderna-mrna-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-beone-medicines-onc-moderna-mrna-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765059.SGD","LABU","BK4568","LU1057294990.SGD","LU2265009873.SGD","LU0511384066.AUD","LU0708995401.HKD","MDCO","BK4548","LU0175139822.USD","LU2125910179.SGD","BK4533","HCSG","LU0820562030.AUD","IE00BQXX3D17.EUR","IE000M9KFDE8.USD","LU2125910336.SGD","MRNY","MRNX","LU0528227936.USD","LU1791710400.SGD","LU0820561818.USD","LU1791710582.SGD","LU1974910355.USD","BK4139","BK4588","MRNA","ONC","IE00BKVL7J92.USD","LU1923622614.USD","BK4551","LU2112291526.USD","XBI","XLV","LU0157215616.USD","LU0882574055.USD","SGXZ23171101.USD","IE0004445239.USD","BK4585","LU0820561909.HKD","LU0107464264.USD","LU2125909247.SGD","LU1267930730.SGD","LU0029874061.USD","LU0128526141.USD","LU0097036916.USD","LU1023059063.AUD","LU1366333091.USD","SG9999013999.USD","DHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640943011","title":"TD Cowen Remains a Buy on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640943011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640943011?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:58","pubTimestamp":1780405082,"startTime":"0","endTime":"0","summary":"In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on BeOne Medicines, with a price target of $424.00. Werber covers th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-remains-a-buy-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4566","BK4207","TD","BK4585","ONC","MDCO","BK4139","BK4526","COWN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294332","title":"Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines (ONC) and Autonomix Medical, Inc. (AMIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294332?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:41","pubTimestamp":1780404062,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bioline RX Ltd Sponsored ADR (BLRX), BeOne Medicines...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bioline-rx-ltd-sponsored-adr-blrx-beone-medicines-onc-and-autonomix-medical-inc-amix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0029874061.USD","BK4588","BK4581","AMIX","BK4082","BK4585","ONC","BK4139","LU0128526141.USD","HCSG","BK4526","LABU","XBI","XLV","MDCO","BLRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910589","title":"RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910589","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910589?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:40","pubTimestamp":1780400423,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Leonid Timashev maintained a Buy rating on BeOne Medicines today and set a price target of $436.00. According to TipRanks, Tima...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-buy-rating-on-beone-medicines-onc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","MDCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640997218","title":"Beone Medicines : RBC Raises Target Price to $436 From $425","url":"https://stock-news.laohu8.com/highlight/detail?id=2640997218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640997218?lang=en_us&edition=fundamental","pubTime":"2026-06-02 14:32","pubTimestamp":1780381950,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nFWN42A03G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688235","BK4585","BK4139","BK4526","BK0239","ONC","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955081","title":"BeOne Medicines Says Its Experimental Cancer Therapies Showed 'Promising' Results at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955081","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955081?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:10","pubTimestamp":1780312221,"startTime":"0","endTime":"0","summary":"BeOne Medicines  said Monday that new data presented at the 2026 American Society of Clinical Oncology meeting showed encouraging activity across its breast, ovarian and liver cancer programs.The company reported that its CDK4 inhibitor BGC-43395 achieved confirmed response rates of up to 68.4% in first-line HR-positive, HER2-negative metastatic breast cancer, supporting the start of a phase 3 trial.Its B7-H4-targeting antibody-drug conjugate BG-C9074 produced a confirmed overall response rate of 45.5% in ovarian cancer patients, while bispecific antibody BGB-B2033 delivered confirmed response rates of 28.9% in heavily pretreated hepatocellular carcinoma patients.BeOne said the results support plans to advance several solid tumor candidates into pivotal-stage development during 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","MDCO","BK4526","ONC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639069747","title":"New Combo Trial in Esophageal Cancer: What LBL-007’s Phase 2 Update Means for ONC Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2639069747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639069747?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:31","pubTimestamp":1779985890,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. The phase 2 study “A Phase 2, Randomized, Active-Controlled, Open-Label...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-combo-trial-in-esophageal-cancer-what-lbl-007s-phase-2-update-means-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-combo-trial-in-esophageal-cancer-what-lbl-007s-phase-2-update-means-for-onc-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4526","ISBC","BK4211","BK4139","ONC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":138,"code":"91000000","status":"200"}]}}